23andme Holding CO 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
23andMe Holding Co. reports significant revenue decline and ongoing losses, confirming a wind-down of operations following the sale of most assets to a related party.
23andMe reports a mixed Q3 with revenue increase driven by a GSK agreement, but expresses substantial doubt about its ability to continue as a going concern.
23andMe's Q2 2025 results show a decrease in revenue and a net loss, alongside strategic changes including a reverse stock split and the closure of its Therapeutics business, raising concerns about its ability to continue as a going concern.
23andMe's first quarter results show a significant revenue decrease year-over-year, alongside ongoing strategic review and a preliminary acquisition proposal.
23andMe's Q3 2024 results reveal a significant net loss, driven by a goodwill impairment charge and decreased revenue, alongside ongoing efforts to address a cyber security incident and Nasdaq listing compliance.